Reviva Pharmaceuticals Holdings Inc expected to post a loss of 11 cents a share - Earnings Preview

Reviva Pharmaceuticals Holdings

08/08/2025 19:20

Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Reviva Pharmaceuticals Holdings Inc is for a loss of 11 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $10.00, about 95.7% above its last closing price of $0.43

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.18
-0.18
-0.13
Beat
28.8
Dec. 31 2025
-0.22
-0.21
-0.15
Beat
30.2
Sep. 30 2024
-0.27
-0.25
-0.25
Met
-1.6​
Jun. 30 2024
-0.29
-0.29
-0.26
Beat
10.3
​​Mar. 31 2024
-0.36
-0.38
-0.25
Beat
33.6
Dec. 31 2023
-0.35
-0.35
Met
0.7​
Sep. 30 2023
-0.43
-0.37
-0.44
Missed
-20.2
Jun. 30 2023
-0.31
-0.28
-0.55
Missed
-99.3

This summary was machine generated August 8 at 18:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)